Vericel sees negligible impact from U.S. tariffs on COGS and gross margin

Vericel Corp

All operations in U.S.; 100% of 2025 revenue from domestic sales.
Majority of manufacturing costs are fixed labor/overhead for MACI and Epicel.
Materials primarily from U.S. suppliers; imported material costs limited.
Maintains safety stock of NexoBrid and ACI-Maix collagen membrane.
Expects negligible impact on COGS and gross margin in 2025 and 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.